Patents by Inventor Birgit Bramlage

Birgit Bramlage has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF GLUCOCORTICOID RECEPTOR (GCR) GENES
    Publication number: 20110020300
    Abstract: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a GCR gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a GCR gene using said pharmaceutical composition; and methods for inhibiting the expression of GCR in a cell.
    Type: Application
    Filed: May 14, 2010
    Publication date: January 27, 2011
    Applicant: GENENTECH, INC.
    Inventors: JACQUES BAILLY, AGNÈS BÉNARDEAU, BIRGIT BRAMLAGE, RAINER CONSTIEN, ANDREA FORST, MARKUS HOSSBACH, BRIGITTE SCHOTT
  • RNAi Modulation of AHA and Therapeutic Uses Thereof
    Publication number: 20110003882
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Application
    Filed: September 7, 2010
    Publication date: January 6, 2011
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • Compositions And Methods For Inhibiting Expression Of Huntingtin Gene
    Publication number: 20100298405
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: April 2, 2009
    Publication date: November 25, 2010
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • RNAi MODULATION OF HIF-1 AND THERAPUTIC USES THEREOF
    Publication number: 20100292305
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1?, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Application
    Filed: April 2, 2010
    Publication date: November 18, 2010
    Inventors: Akin Akinc, Antonin de Fougerolles, Hans-Peter Vornlocher, Philipp Hadwiger, Birgit Bramlage
  • RNAi modulation of Aha and therapeutic uses thereof
    Patent number: 7812150
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: October 12, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • DSRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTIONS
    Publication number: 20100249052
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
    Type: Application
    Filed: March 25, 2008
    Publication date: September 30, 2010
    Inventors: John Benson, Kevin Fitzgerald, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A GENE FROM THE JC VIRUS
    Publication number: 20100227915
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.
    Type: Application
    Filed: March 9, 2010
    Publication date: September 9, 2010
    Inventors: Pamela Tan, Dinah Sah, Birgit Bramlage
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PTP1B GENES
    Publication number: 20100197773
    Abstract: This invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a PTP1B gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a PTP1B gene using said pharmaceutical composition; and methods for inhibiting the expression of PTP1B in a cell.
    Type: Application
    Filed: January 29, 2010
    Publication date: August 5, 2010
    Inventors: Birgit Bramlage, Rainer Constien, Andrea Forst, Markus Hossbach, John Reidhaar-Olson, Cristina Martha Rondinone, Hans-Peter Vornlocher
  • Compositions and methods for inhibiting expression of Huntingtin gene
    Patent number: 7749978
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: November 26, 2007
    Date of Patent: July 6, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • RNAi modulation of HIF-1 and therapeutic uses thereof
    Patent number: 7737265
    Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of HIF-1?, such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: June 15, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Akin Akinc, Antonin De Fougerolles, Hans-Peter Vornlocher, Philipp Hadwiger, Birgit Bramlage
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENES
    Publication number: 20100124547
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Factor VII gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a Factor VII gene using said pharmaceutical composition; and methods for inhibiting the expression of Factor VII in a cell.
    Type: Application
    Filed: November 12, 2009
    Publication date: May 20, 2010
    Inventors: Birgit Bramlage, Rainer Constien, Jacques Himber, Markus Hossbach, Pamela Tan, Hans-Peter Vornlocher
  • Compositions and methods for inhibiting expression of a gene from the JC virus
    Patent number: 7691824
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: April 6, 2010
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Dinah Sah, Birgit Bramlage
  • Compositions and Methods for Inhibiting Expression of the MYC Gene
    Publication number: 20100016405
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the MYC gene (MYC gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the MYC gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by MYC gene expression and the expression of the MYC gene using the pharmaceutical composition.
    Type: Application
    Filed: July 9, 2007
    Publication date: January 21, 2010
    Applicant: ALNYLAM PHARMACEUTICALS, INC
    Inventors: David Bumcrot, Birgit Bramlage, Tan Pamela
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 7605251
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the proprotein convertase subtilisin kexin 9 (PCSK9) gene, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; and methods for treating diseases caused by PCSK9 gene expression by using the pharmaceutical composition.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: October 20, 2009
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION
    Publication number: 20090247607
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
    Type: Application
    Filed: March 23, 2007
    Publication date: October 1, 2009
    Inventors: John Benson, Birgit Bramlage, Kevin Fitzgerald, Pamela Tan, Hans-Peter Vornlocher
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE
    Publication number: 20080221055
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: November 26, 2007
    Publication date: September 11, 2008
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
    Publication number: 20080113930
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: May 10, 2007
    Publication date: May 15, 2008
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor Kotelianski
  • RNAi MODULATION OF AHA AND THERAPEUTIC USES THEREOF
    Publication number: 20080113931
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an Aha gene (Aha1 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an Aha gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier, methods for treating diseases caused by Aha1 expression and the expression of an Aha gene using the pharmaceutical composition; and methods for inhibiting the expression of an Aha gene in a cell.
    Type: Application
    Filed: May 18, 2007
    Publication date: May 15, 2008
    Inventors: Rainer Constien, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, William Balch
  • Compositions and methods for inhibiting expression of Huntingtin gene
    Patent number: 7320965
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: January 22, 2008
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Dinah Wen-Yee Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot
  • Compositions and methods for inhibiting expression of huntingtin gene
    Publication number: 20070099860
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Huntingtin gene (HD gene), comprising an antisense strand having a nucleotide sequence which is less than 25 nucleotides in length and which is substantially complementary to at least a part of the HD gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the HD gene, or a mutant form thereof, using the pharmaceutical composition; and methods for inhibiting the expression of the huntingtin gene in a cell.
    Type: Application
    Filed: October 27, 2006
    Publication date: May 3, 2007
    Inventors: Dinah Sah, Philipp Hadwiger, Ingo Roehl, Birgit Bramlage, Pamela Tan, Hans-Peter Vornlocher, David Bumcrot